ImmunityBio (IBRX) Revenue & Revenue Breakdown
ImmunityBio Revenue Highlights
Latest Revenue (Y)
$14.74M
Latest Revenue (Q)
$1.05M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
ImmunityBio Revenue by Period
ImmunityBio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $14.74M | 2270.58% |
| 2023-12-31 | $622.00K | 159.17% |
| 2022-12-31 | $240.00K | -74.30% |
| 2021-12-31 | $934.00K | 54.38% |
| 2020-12-31 | $605.00K | -72.52% |
| 2019-12-31 | $2.20M | 4585.11% |
| 2018-12-31 | $47.00K | 4.44% |
| 2017-12-31 | $45.00K | 2.27% |
| 2016-12-31 | $44.00K | -81.36% |
| 2015-12-31 | $236.00K | -63.18% |
| 2014-12-31 | $641.00K | 6.83% |
| 2013-12-31 | $600.00K | - |
ImmunityBio generated $14.74M in revenue during NA 2024, up 2270.58% compared to the previous quarter, and up 669.62% compared to the same period a year ago.
ImmunityBio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $1.05M | 2517.50% |
| 2024-03-31 | $40.00K | -71.22% |
| 2023-12-31 | $139.00K | 69.51% |
| 2023-09-30 | $82.00K | 100.00% |
| 2023-06-30 | $41.00K | -88.61% |
| 2023-03-31 | $360.00K | 393.15% |
| 2022-12-31 | $73.00K | -38.14% |
| 2022-09-30 | $118.00K | 237.14% |
| 2022-06-30 | $35.00K | 150.00% |
| 2022-03-31 | $14.00K | -96.41% |
| 2021-12-31 | $390.00K | 490.91% |
| 2021-09-30 | $66.00K | -80.53% |
| 2021-06-30 | $339.00K | 143.88% |
| 2021-03-31 | $139.00K | -194.56% |
| 2020-12-31 | $-147.00K | -197.35% |
| 2020-09-30 | $151.00K | -65.37% |
| 2020-06-30 | $436.00K | 164.24% |
| 2020-03-31 | $165.00K | -82.07% |
| 2019-12-31 | $920.00K | 7566.67% |
| 2019-09-30 | $12.00K | -29.41% |
| 2019-06-30 | $17.00K | 240.00% |
| 2019-03-31 | $5.00K | -28.57% |
| 2018-12-31 | $7.00K | -77.42% |
| 2018-09-30 | $31.00K | 675.00% |
| 2018-06-30 | $4.00K | -20.00% |
| 2018-03-31 | $5.00K | -58.33% |
| 2017-12-31 | $12.00K | 50.00% |
| 2017-09-30 | $8.00K | -42.86% |
| 2017-06-30 | $14.00K | 27.27% |
| 2017-03-31 | $11.00K | -21.43% |
| 2016-12-31 | $14.00K | 16.67% |
| 2016-09-30 | $12.00K | - |
| 2016-06-30 | $12.00K | 100.00% |
| 2016-03-31 | $6.00K | -57.14% |
| 2015-12-31 | $14.00K | 40.00% |
| 2015-09-30 | $10.00K | -89.01% |
| 2015-06-30 | $91.00K | - |
ImmunityBio generated $1.05M in revenue during Q2 2024, up 2517.50% compared to the previous quarter, and up 290.83% compared to the same period a year ago.
ImmunityBio Revenue Breakdown
ImmunityBio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 |
|---|---|
| Product and Service, Other | $595.00K |
| Product | $14.15M |
ImmunityBio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (95.96%), and Product and Service, Other (4.04%).
Quarterly Revenue by Product
| Product/Service | Dec 24 | Sep 24 |
|---|---|---|
| Product | $8.20M | $5.95M |
| Product and Service, Other | $443.00K | $152.00K |
ImmunityBio's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Product (94.87%), and Product and Service, Other (5.13%).
ImmunityBio Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Europe | $531.00K | $591.00K | $198.00K | $561.00K |
| UNITED STATES | $14.21M | $31.00K | $42.00K | $373.00K |
ImmunityBio's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (96.40%), and Europe (3.60%).
Quarterly Revenue by Country
| Country | Mar 18 |
|---|---|
| San Diego California | $100.00K |
ImmunityBio's latest quarterly revenue breakdown by geography, as of Mar 18: San Diego California (100.00%).
ImmunityBio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ARDX | Ardelyx | $333.62M | $98.24M |
| KRYS | Krystal Biotech | $290.51M | $83.84M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| VIR | Vir Bio | $74.20M | $2.38M |
| CVAC | CureVac | $52.70M | $12.37M |
| LXRX | Lexicon Pharmaceuticals | $31.08M | $1.74M |
| IBRX | ImmunityBio | $14.74M | $1.05M |
| BLRX | BioLineRx | $4.80M | $6.86M |
| XFOR | X4 Pharmaceuticals | $2.56M | $560.00K |
| MCRB | Seres Therapeutics | - | - |
| VKTX | Viking Therapeutics | - | - |
| TGTX | TG Therapeutics | - | $83.88M |
| PDSB | PDS Bio | - | - |
| ELEV | Elevation Oncology | - | - |